Quince Therapeutics raises USD 115 million in private placement of Series C preferred shares

Quince Therapeutics priced a private placement, issuing 144,200 shares of Series C Non-Voting Convertible Preferred Stock for about $115 million.

• Each Series C share converts into 52 common shares, subject to conditions tied to stockholder approval.
• The financing included warrants for 72,100 Series C shares at an exercise price of $996.9 per share.
• Warrant exercise could raise about $72 million in additional proceeds.
• The financing closed May 21, 2026, alongside the Orphai acquisition announced May 18, 2026.